In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model | Zendy

Sachin Bhagwat | Zendy; Hariharan Periasamy | Zendy; Swapna Takalkar | Zendy; Rajesh Chavan | Zendy; Pavan Tayde | Zendy; Amol Kulkarni | Zendy; Jaikumar Satav | Zendy; Vineet Zope | Zendy; Mahesh Patel | Zendy

Open Access

In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model

Author(s) -

Sachin Bhagwat,

Hariharan Periasamy,

Swapna Takalkar,

Rajesh Chavan,

Pavan Tayde,

Amol Kulkarni,

Jaikumar Satav,

Vineet Zope,

Mahesh Patel

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00909-19

Subject(s) - staphylococcus aureus , pharmacokinetics , in vivo , prodrug , pharmacology , pharmacodynamics , antibiotics , medicine , microbiology and biotechnology , quinolone , antibacterial agent , drug , biology , bacteria , genetics

Levonadifloxacin is a novel benzoquinolizine subclass of fluoroquinolone, active against quinolone-resistantStaphylococcus aureus . A phase 3 trial for levonadifloxacin and its oral prodrug was recently completed. The present study identified area under the concentration-time curve for the free, unbound fraction of a drug divided by the MIC (f AUC/MIC) as an efficacy determinant for levonadifloxacin in a neutropenic murine lung infection model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research